

ForPatients

by Roche

CRC With Atopic Asthma CRC With Chronic Obstructive Pulmonary Disease CRC With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis Chronic Refractory Cough (CRC) With Non-atopic Asthma Unexplained Chronic Cough

A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough

Trial Status

Recruiting

Trial Runs In

4 Countries

Trial Identifier

NCT05660850 GA43590

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This Phase IIa, multicenter, randomized, double-blind, placebo-controlled, crossover study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamic (PD) effects of GDC-6599 compared with placebo in patients with a history of chronic cough.

Genentech, Inc.

Sponsor

Phase 2

Phase

NCT05660850 GA43590

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=18 Years & <= 80 Years

Healthy Volunteers

No
